Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis
| Autor: | Susanna Bortolusso Ali, L King, Jennifer Knight-Madden, Andre Waugh, Marvin Reid, Colette Cunningham-Myrie, Abdullahi O. Abdulkadri |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Stroke recurrence business.industry Developing country Hematology Disease Cost-effectiveness analysis medicine.disease Oncology Pediatrics Perinatology and Child Health medicine Physical therapy Transfusion therapy Outcomes research business Intensive care medicine Stroke Incremental cost-effectiveness ratio |
| Zdroj: | Pediatric Blood & Cancer. 62:1862-1864 |
| ISSN: | 1545-5009 |
| DOI: | 10.1002/pbc.25563 |
| Popis: | We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death. We followed 43 children with sickle cell disease from 2000 to 2009 after having a first clinical stroke, of whom 10 opted for HU therapy. HU use led to decreased stroke recurrence and death without significantly increasing the annual cost of care per patient (J$83,250 vs. J$76,901, P = 0.491). The incremental cost effectiveness ratio (ICER) for prevention of stroke recurrence amounted to J$169,238 (US$1,900), while that for death prevention equalled J$635,843 (US$7,140). HU may be recommended when safe and affordable transfusion therapy is not feasible. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text